EyePoint Pharmaceuticals, Inc.(EYPT)Earnings, Financials & Key RatiosEyePoint Pharmaceuticals, Inc. (EYPT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current cash burn rate and the $84.8M net loss reported in 2026Q1 suggest an unsustainable financial trajectory without immediate clinical success or additional capital infusion.
EyePoint Pharmaceuticals, Inc. (EYPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
EyePoint Pharmaceuticals, Inc. (EYPT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.99vs $0.79-25.3% | $696,000vs $352,833+97.3% |
| Q2 2026 | Mar 4, 2026 | $0.81vs $0.78-3.8% | $620,000vs $994,464-37.7% |
| Q4 2025 | Nov 5, 2025 | $0.85vs $0.77-10.4% | $966,000vs $1M-4.0% |
| Q3 2025 | Aug 6, 2025 | $0.85vs $0.67-26.9% | $5Mvs $4M+29.2% |
Recent stock market news and headlines for EyePoint Pharmaceuticals, Inc. (EYPT)
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Key metrics vs top competitors for EyePoint Pharmaceuticals, Inc. (EYPT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.02 | $1.17B | -4.42 | -27.5% | -739.42% | -72.19% | — | |
| $10.33 | $2.26B | -7.27 | -18.67% | -558.24% | -64.55% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $2.23 | $134.52M | -3.98 | — | — | -0% | — | |
| $1.51 | $33.11M | -0.46 | — | — | -1335.64% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — |
EyePoint Pharmaceuticals, Inc. (EYPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EyePoint Pharmaceuticals, Inc. (EYPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Apr 13, 2026·SEC
Mar 20, 2026·SEC
Get notified when EYPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EyePoint Pharmaceuticals, Inc. (EYPT) stock FAQ — growth, dividends, profitability & financials explained
EyePoint Pharmaceuticals, Inc. (EYPT) reported $7.6M in revenue for fiscal year 2025. This represents a 10142% increase from $0.1M in 2003.
EyePoint Pharmaceuticals, Inc. (EYPT) saw revenue decline by 27.5% over the past year.
EyePoint Pharmaceuticals, Inc. (EYPT) reported a net loss of $271.6M for fiscal year 2025.
EyePoint Pharmaceuticals, Inc. (EYPT) has a return on equity (ROE) of -72.2%. Negative ROE indicates the company is unprofitable.
EyePoint Pharmaceuticals, Inc. (EYPT) had negative free cash flow of $190.0M in fiscal year 2025, likely due to heavy capital investments.
